ArticleJACC. Advances2026
Associations of Left Atrial Dimension and Ventricular Mass With Long-Term Health Outcomes: Framingham Heart Study.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigher left atrial end-systolic dimension (LASD) and left ventricular mass (LVM) are associated with higher risk of cardiovascular disease (CVD) over short-term follow-up (<10 years). However, data on long-term associations are limited.
objectivesThe objective of the study was to evaluate associations of echocardiography-derived LASD and LVM with risk of mortality, CVD, dementia, hypertension, diabetes, and chronic kidney disease over long-term follow-up among Framingham participants.
methodsClinical covariates and up to 3 serial echocardiographic observations were collected from 1991 to 2008 (median follow-up 17 years; range: 0-29 years). Analyses of incident outcomes excluded those with prevalent disease or missing outcomes.
resultsAmong 8,192 participants (mean age 48 ± 13 years, 54.3% women), we observed 1,245 deaths, 946 CVD, 290 dementia, 1,565 hypertension, 463 diabetes, and 583 chronic kidney disease events. Higher LASD and LVM were associated with higher risk of all outcomes (modeled separately; all P < 0.05), except for coronary heart disease. Participants with higher LASD and LVM (modeled jointly) had higher death and CVD risk, including hard and atherosclerotic CVD (HR per-SD ranged from 1.18-1.28; all P < 0.001). Higher LASD (HR: 1.39; 95% CI: 1.06-1.84) and LVM (HR: 1.37, 95% CI: 1.08-1.74) were associated with higher risk of HF with preserved ejection fraction, whereas higher LVM was associated with higher risk of HF with reduced ejection fraction (HR: 2.13; 95% CI: 1.63-2.78), per-SD increase.
conclusionsIn our large community-based sample, we observed associations of LASD and LVM with risk of multiple health outcomes over long-term follow-up. These findings underscore the importance of maintaining optimal LASD and LVM values over the life course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.